Correction to: Risk factors for lymphopenia in patients with relapsing–remitting multiple sclerosis treated with dimethyl fumarate

被引：0
|
作者：
Fabian Sierra Morales
Igor J. Koralnik
Shiva Gautam
Soleil Samaan
Jacob A. Sloane
机构：
[1] Harvard Medical School,Division of Neuro
[2] Harvard Medical School,Immunology, Department of Neurology, Beth Israel Deaconess Medical Center, Multiple Sclerosis Center
[3] Harvard Medical School,Division of Biostatistics, Department of Medicine, Beth Israel Deaconess Medical Center
来源：
Journal of Neurology | 2020年 / 267卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Unfortunately, the given name and family name of first author was incorrectly tagged in the xml data, therefore it is abbreviated wrongly as “Morales FS” in Pubmed. The correct given name is Fabian and family name is Sierra Morales. Auhtor name should be abbreviated as Sierra Morales F.
引用
收藏
页码：132 / 132
相关论文
共 50 条
  • [41] PATIENT CHARACTERISTICS AND TREATMENT ADHERENCE AMONG PATIENTS TREATED WITH DELAYED-RELEASE DIMETHYL FUMARATE FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN ISRAEL
    Desai, U.
    Huang, M.
    Kirson, N. Y.
    King, S.
    Hellstern, M.
    Schonfeld, S.
    Birnbaum, H. G.
    Lee, A.
    VALUE IN HEALTH, 2017, 20 (05) : A195 - A195
  • [42] Dimethyl fumarate for treating relapsing multiple sclerosis
    Sheremata, William
    Brown, Andrew D.
    Rammohan, Kottil W.
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (01) : 161 - 170
  • [43] Factors associated with dimethyl fumarate induced lymphopenia in a rural multiple sclerosis cohort
    Malik, M. T.
    Zhang, Y.
    Lee, M.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 572 - 572
  • [44] Diroximel fumarate and dimethyl fumarate demonstrate early clinical and radiological efficacy in relapsing-remitting multiple sclerosis
    Singer, Barry A.
    Shafer, S. James
    Arnold, Douglas L.
    Bowen, James D.
    LaGanke, Christopher
    Chen, Hailu
    Hanna, Jerome
    Miller, Catherine
    Leigh-Pemberton, Richard
    Naismith, Robert T.
    NEUROLOGY, 2020, 94 (15)
  • [45] Lymphopenia and eosinophilia in dimethyl fumarate treated patients
    Vinagre Aragon, A.
    Garcia Malo, C.
    Novo Ponte, S.
    Mena Romo, L.
    Moreno Torres, I.
    Blasco Quilez, M. R.
    Garcia Merino, A.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 651 - 651
  • [46] Evaluation of dimethyl fumarate efficacy and safety in patients with relapsing remitting multiple sclerosis switching from other treatments
    Forci, B.
    Mariottini, A.
    Mechi, C.
    Magnani, E.
    Barilaro, A.
    Falcini, M.
    Palumbo, P.
    Massacesi, L.
    Repice, A. M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 490 - 490
  • [47] Effect of dimethyl fumarate on gut microbiota in patients with relapsing remitting multiple sclerosis: a prospective longitudinal pilot study
    Ferri, C.
    Baldin, E.
    Castellazzi, M.
    Caniatti, L. M.
    Baldi, E.
    Pugliatti, M.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 666 - 666
  • [48] Dimethyl fumarate reduces the frequency and function of inflammatory immune cells in relapsing-remitting multiple sclerosis patients
    Diaz, G. Montes
    Fraussen, J.
    Van Wijmeersch, B.
    Hupperts, R.
    Somers, V.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 616 - 617
  • [49] COST-EFFECTIVENESS OF DIMETHYL-FUMARATE COMPARED TO TERIFLUNOMIDE FOR RELAPSING REMITTING MULTIPLE SCLEROSIS PATIENTS IN ITALY
    Mantovani, L. G.
    Furneri, G.
    Cortesi, P. A.
    Santoni, L.
    Prosperini, L.
    Cardillo, A.
    VALUE IN HEALTH, 2020, 23 : S630 - S630
  • [50] Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis
    Alroughani, Raed
    Huppke, Peter
    Mazurkiewicz-Beldzinska, Maria
    Blaschek, Astrid
    Valis, Martin
    Aaen, Gregory
    Pultz, Joe
    Peng, Xiaomei
    Beynon, Vanessa
    FRONTIERS IN NEUROLOGY, 2021, 11
12345